Member Info for Soupdragon78

.... one day.....something will happen...

It’s just a typo. Nothing more.

I do like that the company is telling us that none of the major shareholder will sell over the next two weeks. ;-)

“As at 31 July 2020 the Company is aware of the following notifiable interests in its voting rights:”

In other news, Vistagen is looking quite happy as well today.

Dissapointing it dropped off but glad its finished positive and some big sells cleared out.

Hayashi, don’t know enough about SNG to know the full story, but looks like their news today is about their specific drug. So not a direct relationship to NfX.

What is relevant is seeing the effect on Mcap that positive news can have. With SNG teaching 350m mcap today, if NFX were to do the same (and I don’t see why not) we would sit at 70p

Needs to hang on to this rise now.

Lol Barwickman, we knew you couldn’t resist.

Would have thought you’d prefer Blazin’ Squad version Goup. ;-)

Indeed Random, but the fact that they have a Chief Scientific Advisor now means he must be doing something.

Looking back at the rns for the first patent filing it does talk with the language of short term possibilities, plus it is over ten months since it’s filing.

Just a thought.

“...This first resulting patent filing relates to novel forms of a naturally-occurring cannabinoid, which is the subject of growing scientific interest as its therapeutic promise becomes increasingly validated. The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, which in due course, will generate further milestone payments, plus royalties to Nuformix of 20% under the Agreement terms.”

How long before Ebers announce their first product?

Why do we think Kissei competitors are not interested? Why does it have to be Kissei just because they developed tranilast?

Exactly Halespur, partly why I feel Kissei are not part of negotiations.

Yuyu’s, if you work for a salary of 100k for 12 years, would you turn down £5.5m on off payment?

Yuyu’s, I doubt the major shareholder would reject 14p.
For DG and JH that would be £5.5m . Not a bad payout.

Jeff Bezos $113bn
Bill Gates $98bn
Mark Zuckerberg $78bn

Not far for me to go!!!

Just to make sure we have all the info, can you tell us... is it peas or beans with your fish fingers tonight? We need to know.

Thank god for that Bertie I’ve been worried about what your strategy was for the past 5 years since you registered with this site.

Bit of a quiet day, so having a dig around (somewhat out of frustration) and dug up this little number. Apologies if its been here before.

I can't remember if the trial it refers to is the same as the one previously mentioned here. But either way its a good reminder that not only does NXP002 relate to IPF as a result of COVID, but there is an opportunity for it to relate to other aspects of the treatment of the virus.

https://www.jimmunol.org/content/jimmunol/early/2020/06/02/jimmunol.2000513.full.pdf

"Several repurposed compounds with regulatory effects on inflammasome activity are currently being appraised in clinical
trials as treatment for COVID-19.

An example is tranilast, a tryptophan analogue that has a direct inhibitory action against NLRP3 (52), which is currently undergoing a randomized control trial in COVID-19 patients (registration number: ChiCTR2000030002 on the Chinese Clinical Trial Registry). Tranilast is initially approved for the treatment of allergic and inflammatory diseases such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids, and hypertrophic scars (53). Now, its effectiveness has also been recognized in the treatment of fibrosis, proliferative disorders, cancer, ardiovascular problems, autoimmune disorders, ocular diseases, diabetes, and renal diseases (53).

Tranilast might be an attractive intervention for COVID-19 patients with comorbidities, given its wide array of therapeutic effects with minimal side effects""

Johnny, good to hear you went to a top private hospital and not one of the bad private hospitals.